Susumu Tonegawa, the first Japanese citizen to win the Nobel Prize in Physiology or Medicine, died July 11 [2] at the age of 86 [1].
Tonegawa's work transformed the understanding of the human immune system. By uncovering how the body generates a vast array of antibodies to fight diverse pathogens, he provided the foundational science for modern immunology and the development of targeted medical therapies.
The Massachusetts Institute of Technology (MIT) announced the death of the professor [2]. While a specific location of death was not disclosed, burial is planned for Kyoto [2]. No official cause of death was provided, though reports indicate the death appeared to be from natural causes [2].
Born in Nagoya [2], Tonegawa graduated from Kyoto University before pursuing research at the Basel Institute for Immunology in Switzerland and later joining the faculty at MIT [2]. His career was defined by a rigorous approach to scientific inquiry and a willingness to challenge established norms.
In 1987 [1], Tonegawa received the Nobel Prize for his discovery of somatic hypermutation, the process by which antibodies evolve to become more effective during an infection. This discovery solved a long-standing biological puzzle regarding how a limited number of genes could produce millions of different antibodies.
Reflecting on his scientific journey, Tonegawa once described his initial reaction to certain breakthroughs as skeptical. "At first, I was half-doubting, or rather, 90% of me was doubting, and I thought there must be some mistake," Tonegawa said. "Science is, after all, interesting—and it must be interesting first, or it is no good," he said [1].
“Science is, after all, interesting—and it must be interesting first, or it is no good.”
Tonegawa's death marks the loss of a pioneer who bridged Japanese and Western scientific communities. His research into antibody diversity didn't just earn a Nobel Prize; it enabled the creation of monoclonal antibodies and other biotechnology tools currently used to treat cancers and autoimmune diseases globally.
